The authors report the clinical, neuroradiologic, and neuromuscular pathological findings in a patient with GM1 gangliosidosis. The proton magnetic resonance spectroscopy, previously reported in a single patient with GM1 gangliosidosis, detected a mild reduction of N-acetylaspartate, consistent with relative paucity of axons and neurons and increased levels of myoinositol suggestive of gliotic white matter changes along with the accumulation of an additional compound that could represent either guanidinoacetate or Gal beta 1-6Gal beta 1-4)GlcNAc, an oligosaccharide previously isolated from the urine of GM1 gangliosidosis patients. Although these findings will have to be further confirmed in more patients with GM1 gangliosidosis, they suggest that proton magnetic resonance spectroscopy may provide useful end points to assess the efficacy of novel treatments that could soon become clinically available. Histologically, no significant alterations were found in axons, but there was evidence of redundant and inappropriately folded myelin, which is a feature attributed to disturbed axon-glial interactions.
O'Brien JS, Stern MB, Landing BH, O'Brien JK, Donnell GNGeneralized gangliosidosis: another inborn error of ganglioside metabolism?Am J Dis Child.1965;109:338-346.
3.
Zimmerman RA , Wang ZJThe value of proton MR spectroscopy in pediatric metabolic brain disease. AJNR Am J Neuroradiol.1997;18(10):1872-1879.
4.
Kuker W., Ruff J., Gaertner S., et al. Modern MRI tools for the characterization of acute demyelinating lesions: value of chemical shift and diffusion-weighted imaging. Neuroradiology. 2004;46(6):421-426.
5.
Wenger DA, Tarby TJ, Wharton C.Macular cherry-red spots and myoclonus with dementia: coexistent neuraminidase and beta-galactosidase deficiencies. Biochem Biophys Res Commun.1978;82(2):589-595.
6.
Provencher SWEstimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med.1993; 30(6):672-679.
7.
Georgiou T., Drousiotou A., Campos Y., et al. Four novel mutations in patients from the Middle East with the infantile form of GM1-gangliosidosis. Hum Mutat.2004;24(4):352.
8.
Michalski JC , Lemoine J., Wieruszeski JM, et al. Characterization of a novel type of chain-terminator Gal beta 1-6Gal beta 1-4)GlcNAc in an oligosaccharide related to N-glycosylated protein glycans isolated from GM1 the urine of patients with gangliosidosis. Eur J Biochem.1991;198(2):521-526.
9.
Chiu NC, Qian WH, Shanske AL, et al. A common mutation site in the beta-galactosidase gene originates in Puerto Rico. Pediatr Neurol.1996;14(1):53-56.
10.
Gururaj A., Sztriha L., Hertecant J., et al. Magnetic resonance imaging findings and novel mutations in GM1 gangliosidosis. J Child Neurol.2005;20(1):57-60.
11.
Gascon GG, Ozand PT, Erwin REGM1 gangliosidosis type 2 in two siblings. J Child Neurol.1992;7(suppl):S41-S50.
12.
van der Voorn JP, Pouwels PJ, Kamphorst W., et al. Histopathologic correlates of radial stripes on MR images in lysosomal storage disorders. AJNR Am J Neuroradiol.2005;26(3):442-446.
13.
Di Rocco M , Rossi A., Parenti G., et al. Different molecular mechanisms leading to white matter hypomyelination in infantile onset lysosomal disorders. Neuropediatrics. 2005;36(4):265-269.
14.
Erol I., Alehan F., Ali Pourbagher M., et al. Neuroimaging findings in infantile GM1 gangliosidosis. Eur J Paediatr Neurol.2006;10(5-6):245-248.
15.
Mathews PM, Andermann F., Silver K., et al. Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies. Neurology. 1993;43(12):2484-2490.
16.
Barkovich AJ , Good WV, Koch TK, et al. Mitochondrial disorders: analysis of their clinical and imaging characteristics. AJNR Am J Neuroradiol.1993;14(5):1119-1137.
17.
Kruse B., Hanefeld F., Christen HJ, et al. Alterations of brain metabolites in metachromatic leukodystrophy as detected by localized proton magnetic resonance spectroscopy in vivo. J Neurol.1993;241(2):68-74.
18.
Sylvain M., Arnold DL, Scriver CR, et al. Magnetic resonance spectroscopy in Niemann-Pick disease type C: correlation with diagnosis and clinical response to cholestyramine and lovastatin. Pediatr Neurol.1994;10(3):228-232.
19.
Grodd W., Krageloh-Mann I., Klose U., et al. Metabolic and destructive brain disorders in children: findings with localized proton MR spectroscopy. Radiology. 1991;181(1):173-181.
20.
Brockmann K. , Dechent P., Wilken B., et al. Proton MRS profile of cerebral metabolic abnormalities in Krabbe disease. Neurology . 2003;60(5):819-825.
21.
Arnold DL, Matthews PM, Francis G., et al. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease . Magn Reson Med.1990;14(1):154-159.
22.
Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain. 1994;117(pt 1):49-58.
23.
De Stefano N., Matthews PM, Antel JP, et al. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol.1995;38(6):901-909.
24.
Bruhn H., Frahm J., Merboldt KD, et al. Multiple sclerosis in children: cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo. Ann Neurol.1992;32(2):140-150.
25.
Koopmans RA , Li DK, Zhu G., et al. Magnetic resonance spectroscopy of multiple sclerosis: in-vivo detection of myelin breakdown products. Lancet. 1993;341(8845):631-632.
26.
Fisher SK, Novak JE, Agranoff BWInositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. J Neurochem.2002;82(4):736-754.
27.
Kasperzyk JL , d'Azzo A., Platt FM, et al. Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice . J Lipid Res.2005; 46(4):744-751.
28.
Matsuda J., Suzuki O., Oshima A., et al. Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis . Proc Natl Acad Sci U S A. 2003;100(26):15912-15917.
29.
Folkerth RDAbnormalities of developing white matter in lysosomal storage diseases. J Neuropathol Exp Neurol.1999;58(9): 887-902.
30.
Murnane RD, Wright RW Jr, Ahern-Rindell AJ, et al. Prenatal lesions in an ovine fetus with GM1 gangliosidosis. Am J Med Genet.1991;39(1):106-111.
31.
Kaye EM, Alroy J., Raghavan SS, et al. Dysmyelinogenesis in animal model of GM1 gangliosidosis. Pediatr Neurol.1992; 8(4):255-261.
32.
van der Voorn JP, Kamphorst W., van der Knaap MS, et al. The leukoencephalopathy of infantile GM1 gangliosidosis: oligodendrocytic loss and axonal dysfunction . Acta Neuropathol (Berl).2004;107(6):539-545.
33.
Folkerth RD , Alroy J., Bhan I., et al. Infantile G(M1) gangliosidosis: complete morphology and histochemistry of two autopsy cases, with particular reference to delayed central nervous system myelination. Pediatr Dev Pathol. 2000;3(1): 73-86.
34.
Tome FM, Fardeau M.Ultrastructural study of a muscle biopsy in a case of GM1 gangliosidosis type I. Pathol Eur. 1976;11(1): 15-25.
35.
Dayan AD, Graveson GS, Robinson PK, et al. Globular neuropathy: a disorder of axons and Schwann cells. J Neurol Neurosurg Psychiatry. 1968;31(6):552-560.
36.
Vallet JM, Gil R., Leboutet MJ, Hugon J., Moulies D.Congenital hypo- and hypermyelination neuropathy. Acta Neuropathol (Berl).1987;74(2):197-201.
37.
Ohnishi A., Murai Y., Ikeda M., et al. Autosomal recessive motor and sensory neuropathy with excessive myelin outfolding. Muscle Nerve. 1989;12(7):568-575.
38.
Gabreels-Festen AA, Joosten EM, Gabreels FJ, et al. Congenital demyelinating motor and sensory neuropathy with focally folded myelin sheaths. Brain . 1990;113(pt 6):1629-1643.
39.
Umehara F., Takenaga S., Nakagawa M., et al. Dominantly inherited motor and sensory neuropathy with excessive myelin folding complex. Acta Neuropathol (Berl).1993;86(6): 602-608.
40.
Dupree JL, Coetzee T., Suzuki K., et al. Myelin abnormalities in mice deficient in galactocerebroside and sulfatide. J Neurocytol. 1998;27(9):649-659.
41.
Bosio A., Bussow H., Adam J., et al. Galactosphingolipids and axono-glial interaction in myelin of the central nervous system. Cell Tissue Res.1998;292(2):199-210.
42.
Vyas AA, Patel HV, Fromholt SE, et al. Gangliosides are functional nerve cell ligands for myelin-associated glycoprotein (MAG), an inhibitor of nerve regeneration. Proc Natl Acad Sci U S A. 2002;99(12):8412-8417.
